{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:16:05Z","timestamp":1790745365938,"version":"4.1.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s12325-021-01701-1","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T13:05:13Z","timestamp":1618837513000},"page":"2689-2708","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["A Clinical and Budgetary Impact Analysis of Introducing Sugammadex for Routine Reversal of Neuromuscular Blockade in a Hypothetical Cohort in the US"],"prefix":"10.1007","volume":"38","author":[{"given":"Yiling","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori D.","family":"Bash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Saager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,19]]},"reference":[{"key":"1701_CR1","unstructured":"Robertson T, Ridge A. Proposal for update of the anaesthesia and muscle relaxant sections of the WHO; 18th Expert Committee on the Selection and Use of Essential Medicines. 2010. http:\/\/www.who.int\/selection_medicines\/committees\/expert\/18\/applications\/anaesthetic_proposal.pdf. Accessed 10 July 2019."},{"key":"1701_CR2","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1097\/CCM.0b013e31824e0e67","volume":"40","author":"SR Wilcox","year":"2012","unstructured":"Wilcox SR, Bittner EA, Elmer J, et al. Neuromuscular blocking agent administration for emergent tracheal intubation is associated with decreased prevalence of procedure-related complications. Crit Care Med. 2012;40:1808\u201313.","journal-title":"Crit Care Med"},{"key":"1701_CR3","doi-asserted-by":"crossref","unstructured":"Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg. 2010;111:120\u20138.","DOI":"10.1213\/ANE.0b013e3181da832d"},{"key":"1701_CR4","first-page":"97","volume":"72","author":"GS Murphy","year":"2006","unstructured":"Murphy GS. Residual neuromuscular blockade: incidence, assessment, and relevance in the postoperative period. Minerva Anestesiol. 2006;72:97\u2013109.","journal-title":"Minerva Anestesiol"},{"key":"1701_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jclinane.2017.09.005","volume":"43","author":"AW Belcher","year":"2017","unstructured":"Belcher AW, Leung S, Cohen B, et al. Incidence of complications in the post-anesthesia care unit and associated healthcare utilization in patients undergoing non-cardiac surgery requiring neuromuscular blockade 2005\u20132013: a single center study. J Clin Anesth. 2017;43:33\u20138.","journal-title":"J Clin Anesth"},{"key":"1701_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jclinane.2018.12.042","volume":"55","author":"L Saager","year":"2019","unstructured":"Saager L, Maiese EM, Bash LD, et al. Incidence, risk factors, and consequences of residual neuromuscular block in the United States: the prospective, observational, multicenter RECITE-US study. J Clin Anesth. 2019;55:33\u201341.","journal-title":"J Clin Anesth"},{"key":"1701_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1185\/03007995.2015.1103213","volume":"32","author":"B Yu","year":"2016","unstructured":"Yu B, Ouyang B, Ge S, et al. Incidence of postoperative residual neuromuscular blockade after general anesthesia: a prospective, multicenter, anesthetist-blind, observational study. Curr Med Res Opin. 2016;32:1\u20139.","journal-title":"Curr Med Res Opin"},{"key":"1701_CR8","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1213\/ANE.0000000000000757","volume":"121","author":"LP Fortier","year":"2015","unstructured":"Fortier LP, McKeen D, Turner K, et al. The RECITE study: a canadian prospective, multicenter study of the incidence and severity of residual neuromuscular blockade. Anesth Analg. 2015;121:366\u201372.","journal-title":"Anesth Analg"},{"key":"1701_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e6329","volume":"345","author":"M Grosse-Sundrup","year":"2012","unstructured":"Grosse-Sundrup M, Henneman JP, Sandberg WS, et al. Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study. BMJ. 2012;345:e6329.","journal-title":"BMJ"},{"key":"1701_CR10","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1097\/ALN.0000000000001279","volume":"125","author":"CM Bulka","year":"2016","unstructured":"Bulka CM, Terekhov MA, Martin BJ, et al. Nondepolarizing neuromuscular blocking agents, reversal, and risk of postoperative pneumonia. Anesthesiology. 2016;125:647\u201355.","journal-title":"Anesthesiology"},{"key":"1701_CR11","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/bja\/aeq157","volume":"105","author":"A Butterly","year":"2010","unstructured":"Butterly A, Bittner EA, George E, et al. Postoperative residual curarization from intermediate-acting neuromuscular blocking agents delays recovery room discharge\u2020. Br J Anaesth. 2010;105:304\u20139.","journal-title":"Br J Anaesth"},{"key":"1701_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1213\/ane.0b013e31816d1268","volume":"107","author":"GS Murphy","year":"2008","unstructured":"Murphy GS, Szokol JW, Marymont JH, et al. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg. 2008;107:130\u20137.","journal-title":"Anesth Analg"},{"key":"1701_CR13","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1213\/ANE.0000000000001848","volume":"124","author":"MR Bronsert","year":"2017","unstructured":"Bronsert MR, Henderson WG, Monk TG, et al. Intermediate-acting nondepolarizing neuromuscular blocking agents and risk of postoperative 30-day morbidity and mortality, and long-term survival. Anesth Analg. 2017;124:1476\u201383.","journal-title":"Anesth Analg"},{"key":"1701_CR14","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1097\/00000542-199704000-00005","volume":"86","author":"AF Kopman","year":"1997","unstructured":"Kopman AF, Yee PS, Neuman GG. Relationship of the train-of-four fade ratio to clinical signs and symptoms of residual paralysis in awake volunteers. Anesthesiology. 1997;86:765\u201371.","journal-title":"Anesthesiology"},{"key":"1701_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1213\/01.ANE.0000095040.36648.F7","volume":"98","author":"GS Murphy","year":"2004","unstructured":"Murphy GS, Szokol JW, Franklin M, et al. Postanesthesia care unit recovery times and neuromuscular blocking drugs: a prospective study of orthopedic surgical patients randomized to receive pancuronium or rocuronium. Anesth Analg. 2004;98:193\u2013200.","journal-title":"Anesth Analg"},{"key":"1701_CR16","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1213\/ANE.0000000000004028","volume":"128","author":"SD Grabitz","year":"2019","unstructured":"Grabitz SD, Rajaratnam N, Chhagani K, et al. The effects of postoperative residual neuromuscular blockade on hospital costs and intensive care unit admission: a population-based cohort study. Anesth Analg. 2019;128:1129\u201336.","journal-title":"Anesth Analg"},{"key":"1701_CR17","doi-asserted-by":"crossref","unstructured":"Kheterpal S, Vaughn MT, Dubovoy TZ. Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (STRONGER): A multicenter matched cohort analysis. Anesthesiology. 2020;132:1371\u201381.","DOI":"10.1097\/ALN.0000000000003256"},{"key":"1701_CR18","first-page":"266","volume":"41","author":"A Bom","year":"2002","unstructured":"Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl. 2002;41:266\u201370.","journal-title":"Angew Chem Int Ed Engl"},{"key":"1701_CR19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.coph.2006.11.009","volume":"7","author":"A Bom","year":"2007","unstructured":"Bom A, Epemolu O, Hope F, et al. Selective relaxant binding agents for reversal of neuromuscular blockade. Curr Opin Pharmacol. 2007;7:298\u2013302.","journal-title":"Curr Opin Pharmacol"},{"key":"1701_CR20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jclinane.2017.06.006","volume":"41","author":"WJ Herring","year":"2017","unstructured":"Herring WJ, Woo T, Assaid CA, et al. Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: a pooled analysis of 26 studies. J Clin Anesth. 2017;41:84\u201391.","journal-title":"J Clin Anesth"},{"key":"1701_CR21","doi-asserted-by":"crossref","unstructured":"Hristovska AM, Duch P, Allingstrup M, et al. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database Syst Rev. 2017;8:CD012763.","DOI":"10.1002\/14651858.CD012763"},{"key":"1701_CR22","doi-asserted-by":"crossref","unstructured":"Hristovska AM, Duch P, Allingstrup M, et al. The comparative efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. A Cochrane systematic review with meta-analysis and trial sequential analysis. Anaesthesia. 2018;73:631\u201341.","DOI":"10.1111\/anae.14160"},{"key":"1701_CR23","first-page":"233339281664789","volume":"3","author":"N Mihailovic","year":"2016","unstructured":"Mihailovic N, Kocic S, Jakovljevic M. Review of diagnosis-related group-based financing of hospital care. Health Serv Res Manag Epidemiol. 2016;3:2333392816647892-92.","journal-title":"Health Serv Res Manag Epidemiol"},{"key":"1701_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17:5\u201314.","journal-title":"Value Health"},{"key":"1701_CR25","unstructured":"US Department of Veterans Affairs\u2014Health Economics Resource Center (HERC). Budget impact analysis. https:\/\/www.herc.research.va.gov\/include\/page.asp?id=budget-impact-analysis. Accessed 4 Oct 2019."},{"key":"1701_CR26","doi-asserted-by":"crossref","unstructured":"FMCP Format Executive Committee. The AMCP format for formulary submissions version 3.0. J Manag Care Pharm. 2010;16:1\u201330.","DOI":"10.18553\/jmcp.2010.16.S1-A.1"},{"key":"1701_CR27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1741-7015-11-80","volume":"11","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMC Med. 2013;11:80.","journal-title":"BMC Med"},{"key":"1701_CR28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/EJA.0000000000000118","volume":"32","author":"I Jammer","year":"2015","unstructured":"Jammer I, Wickboldt N, Sander M, et al. Standards for definitions and use of outcome measures for clinical effectiveness research in perioperative medicine: european Perioperative Clinical Outcome (EPCO) definitions: a statement from the ESA-ESICM joint taskforce on perioperative outcome measures. Eur J Anaesthesiol. 2015;32:88\u2013105.","journal-title":"Eur J Anaesthesiol"},{"key":"1701_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1213\/ANE.0000000000004505","volume":"131","author":"M Krause","year":"2020","unstructured":"Krause M, McWilliams SK, Bullard KJ, et al. Neostigmine versus sugammadex for reversal of neuromuscular blockade and effects on reintubation for respiratory failure or newly initiated noninvasive ventilation: an interrupted time series design. Anesth Analg. 2020;131:141\u201351.","journal-title":"Anesth Analg"},{"key":"1701_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinane.2020.109804","volume":"64","author":"TS Moon","year":"2020","unstructured":"Moon TS, Reznik S, Pak T, et al. Sugammadex versus neostigmine for reversal of rocuronium-induced neuromuscular blockade: a randomized, double-blinded study of thoracic surgical patients evaluating hypoxic episodes in the early postoperative period. J Clin Anesth. 2020;64:109804.","journal-title":"J Clin Anesth"},{"key":"1701_CR31","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1097\/ACO.0000000000000395","volume":"29","author":"T Fuchs-Buder","year":"2016","unstructured":"Fuchs-Buder T, Nemes R, Schmartz D. Residual neuromuscular blockade: management and impact on postoperative pulmonary outcome. Curr Opin Anaesthesiol. 2016;29:662\u20137.","journal-title":"Curr Opin Anaesthesiol"},{"key":"1701_CR32","unstructured":"Food and Drug Administration. Sugammadex injection\u2014prescribing information. 2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/022225lbl.pdf."},{"key":"1701_CR33","first-page":"1","volume":"3","author":"CD Fryar","year":"2016","unstructured":"Fryar CD, Gu Q, Ogden CL, et al. Anthropometric reference data for children and adults: united States, 2011-2014. Vital Health Stat. 2016;3:1\u201346.","journal-title":"Vital Health Stat"},{"key":"1701_CR34","unstructured":"Food and Drug Administration. Neostigmine methylsulfate injection\u2014prescribing information. 2013. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/204078s000lbl.pdf."},{"key":"1701_CR35","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1517\/14656566.2016.1145667","volume":"17","author":"F Haerter","year":"2016","unstructured":"Haerter F, Eikermann M. Reversing neuromuscular blockade: inhibitors of the acetylcholinesterase versus the encapsulating agents sugammadex and calabadion. Expert Opin Pharmaco. 2016;17:819\u201333.","journal-title":"Expert Opin Pharmacol"},{"key":"1701_CR36","doi-asserted-by":"publisher","first-page":"e507","DOI":"10.1097\/MJT.0000000000000305","volume":"24","author":"TG Monk","year":"2017","unstructured":"Monk TG, Rietbergen H, Woo T, et al. Use of sugammadex in patients with obesity: a pooled analysis. Am J Ther. 2017;24:e507\u201316.","journal-title":"Am J Ther"},{"key":"1701_CR37","doi-asserted-by":"crossref","unstructured":"Horrow J, Li W, Blobner M, et al., editors. Actual versus ideal body weight dosing of sugammadex in the morbidly obese. Anesthesiology; 2019; Orlando, FL, USA.","DOI":"10.21203\/rs.3.rs-52113\/v1"},{"key":"1701_CR38","unstructured":"AnalySource. AnalySource\u00ae: premier access to the First Databank drug pricing database. https:\/\/www.analysource.com\/. Accessed 8 Oct 2019."},{"key":"1701_CR39","unstructured":"Agency for Healthcare Research and Quality. HCUPnet healthcare cost and utilization project. 2015. https:\/\/hcupnet.ahrq.gov\/#setup. Accessed 15 July 2019."},{"key":"1701_CR40","unstructured":"Bureau of Labor Statistics USDoL. Consumer Price Index, May 2019. 2019. https:\/\/www.bls.gov\/cpi\/. Accessed 24 May 2019."},{"key":"1701_CR41","unstructured":"American Medical Association. Policy research perspectives\u2014national health expenditures, 2017. 2019. https:\/\/www.ama-assn.org\/system\/files\/2019-04\/prp-annual-spending-2017.pdf. Accessed 14 Nov 2019."},{"key":"1701_CR42","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12871-018-0605-6","volume":"18","author":"HD de Boer","year":"2018","unstructured":"de Boer HD, Carlos RV, Brull SJ. Is lower-dose sugammadex a cost-saving strategy for reversal of deep neuromuscular block? Facts and fiction. BMC Anesthesiol. 2018;18:159.","journal-title":"BMC Anesthesiol"},{"key":"1701_CR43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12871-017-0348-9","volume":"17","author":"MT Aouad","year":"2017","unstructured":"Aouad MT, Alfahel WS, Kaddoum RN, et al. Half dose sugammadex combined with neostigmine is non-inferior to full dose sugammadex for reversal of rocuronium-induced deep neuromuscular blockade: a cost-saving strategy. BMC Anesthesiol. 2017;17:57.","journal-title":"BMC Anesthesiol"},{"key":"1701_CR44","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12871-019-0817-4","volume":"19","author":"G Domenech","year":"2019","unstructured":"Domenech G, Kampel MA, Garc\u00eda Guzzo ME, et al. Usefulness of intra-operative neuromuscular blockade monitoring and reversal agents for postoperative residual neuromuscular blockade: a retrospective observational study. BMC Anesthesiol. 2019;19:143.","journal-title":"BMC Anesthesiol"},{"key":"1701_CR45","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/ALN.0b013e31818a3fee","volume":"109","author":"RK Jones","year":"2008","unstructured":"Jones RK, Caldwell JE, Brull SJ, et al. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology. 2008;109:816\u201324.","journal-title":"Anesthesiology"},{"key":"1701_CR46","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1097\/EJA.0b013e32833d56b7","volume":"27","author":"M Blobner","year":"2010","unstructured":"Blobner M, Eriksson LI, Scholz J, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. Eur J Anaesthesiol. 2010;27:874\u201381.","journal-title":"Eur J Anaesthesiol"},{"key":"1701_CR47","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1213\/ane.0b013e3181ac53c3","volume":"110","author":"KS Khuenl-Brady","year":"2010","unstructured":"Khuenl-Brady KS, Wattwil M, Vanacker BF, et al. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesth Analg. 2010;110:64\u201373.","journal-title":"Anesth Analg"},{"key":"1701_CR48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1471-2253-10-15","volume":"10","author":"HJ Lemmens","year":"2010","unstructured":"Lemmens HJ, El-Orbany MI, Berry J, et al. Reversal of profound vecuronium-induced neuromuscular block under sevoflurane anesthesia: sugammadex versus neostigmine. BMC Anesthesiol. 2010;10:15.","journal-title":"BMC Anesthesiol"},{"key":"1701_CR49","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/j.1365-2044.2012.07197.x","volume":"67","author":"G Geldner","year":"2012","unstructured":"Geldner G, Niskanen M, Laurila P, et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia. 2012;67:991\u20138.","journal-title":"Anaesthesia"},{"key":"1701_CR50","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1007\/s00101-015-0048-0","volume":"64","author":"N Rahe-Meyer","year":"2015","unstructured":"Rahe-Meyer N, Berger C, Wittmann M, et al. Recovery from prolonged deep rocuronium-induced neuromuscular blockade: a randomized comparison of sugammadex reversal with spontaneous recovery. Anaesthesist. 2015;64:506\u201312.","journal-title":"Anaesthesist"},{"key":"1701_CR51","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1093\/bja\/aev104","volume":"115","author":"B Brueckmann","year":"2015","unstructured":"Brueckmann B, Sasaki N, Grobara P, et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study. Br J Anaesth. 2015;115:743\u201351.","journal-title":"Br J Anaesth"},{"key":"1701_CR52","first-page":"1267","volume":"82","author":"CL Errando","year":"2016","unstructured":"Errando CL, Garutti I, Mazzinari G, et al. Residual neuromuscular blockade in the postanesthesia care unit: observational cross-sectional study of a multicenter cohort. Minerva Anestesiol. 2016;82:1267\u201377.","journal-title":"Minerva Anestesiol"},{"key":"1701_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinane.2020.109818","volume":"64","author":"AD Raval","year":"2020","unstructured":"Raval AD, Uyei J, Karabis A, et al. Incidence of residual neuromuscular blockade and use of neuromuscular blocking agents with or without antagonists: a systematic review and meta-analysis of randomized controlled trials. J Clin Anesth. 2020;64:109818.","journal-title":"J Clin Anesth"},{"key":"1701_CR54","first-page":"735","volume":"82","author":"J Martinez-Ubieto","year":"2016","unstructured":"Martinez-Ubieto J, Ortega-Lucea S, Pascual-Bellosta A, et al. Prospective study of residual neuromuscular block and postoperative respiratory complications in patients reversed with neostigmine versus sugammadex. Minerva Anestesiol. 2016;82:735\u201342.","journal-title":"Minerva Anestesiol"},{"key":"1701_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinane.2020.109962","volume":"66","author":"AD Raval","year":"2020","unstructured":"Raval AD, Anupindi VR, Ferrufino CP, et al. Epidemiology and outcomes of residual neuromuscular blockade: a systematic review of observational studies. J Clin Anesth. 2020;66:109962.","journal-title":"J Clin Anesth"},{"key":"1701_CR56","doi-asserted-by":"crossref","unstructured":"Evron S, Abelansky Y, Ezri T, et al. Respiratory events with sugammadex vs. neostigmine following laparoscopic sleeve gastrectomy: a prospective pilot study assessing neuromuscular reversal strategies. Rom J Anaesth Intensive Care. 2017;24:111\u201314.","DOI":"10.21454\/rjaic.7518.242.evr"},{"key":"1701_CR57","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S2213-2600(18)30294-7","volume":"7","author":"E Kirmeier","year":"2019","unstructured":"Kirmeier E, Eriksson LI, Lewald H, et al. Post-anaesthesia pulmonary complications after use of muscle relaxants (POPULAR): a multicentre, prospective observational study. Lancet Respir Med. 2019;7:129\u201340.","journal-title":"Lancet Respir Med"},{"key":"1701_CR58","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1007\/s12630-019-01419-3","volume":"66","author":"E Alday","year":"2019","unstructured":"Alday E, Mu\u00f1oz M, Planas A, et al. Effects of neuromuscular block reversal with sugammadex versus neostigmine on postoperative respiratory outcomes after major abdominal surgery: a randomized-controlled trial. Can J Anaesth. 2019;66:1328\u201337.","journal-title":"Can J Anaesth"},{"key":"1701_CR59","doi-asserted-by":"crossref","unstructured":"Chae YJ, Joe HB, Oh J, et al. Thirty-day postoperative outcomes following sugammadex use in colorectal surgery patients; retrospective study. J Clin Med. 2019;8:97.","DOI":"10.3390\/jcm8010097"},{"key":"1701_CR60","doi-asserted-by":"crossref","unstructured":"Ezri T, Evron S, Petrov I, et al. Residual curarization and postoperative respiratory complications following laparoscopic sleeve gastrectomy. The effect of reversal agents: sugammadex vs. neostigmine. J Crit Care Med (Targu Mures). 2015;1:61\u201367.","DOI":"10.1515\/jccm-2015-0009"},{"key":"1701_CR61","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.bja.2020.01.016","volume":"124","author":"BM Togioka","year":"2020","unstructured":"Togioka BM, Yanez D, Aziz MF, et al. Randomised controlled trial of sugammadex or neostigmine for reversal of neuromuscular block on the incidence of pulmonary complications in older adults undergoing prolonged surgery. Br J Anaesth. 2020;124:553\u201361.","journal-title":"Br J Anaesth"},{"key":"1701_CR62","unstructured":"Bash LD, Vaughn MT, Jiang Y, et al. Reducing pulmonary complications after surgery in patients receiving reversal of neuromuscular blockade: analysis from the multicenter perioperative outcomes group. Abstract Poster Reception Networking Event, ACS NSQIP Adult Research presented at: ACS Quality and Safety Conference 2019; July 19\u201322, 2019; Washington, DC, U.S.A. 2019."},{"key":"1701_CR63","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/ALN.0b013e31817f5bc7","volume":"109","author":"FK Puhringer","year":"2008","unstructured":"Puhringer FK, Rex C, Sielenkamper AW, et al. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology. 2008;109:188\u201397.","journal-title":"Anesthesiology"},{"key":"1701_CR64","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12871-016-0281-3","volume":"16","author":"RP Insinga","year":"2016","unstructured":"Insinga RP, Joyal C, Goyette A, et al. A discrete event simulation model of clinical and operating room efficiency outcomes of sugammadex versus neostigmine for neuromuscular block reversal in Canada. BMC Anesthesiol. 2016;16:114.","journal-title":"BMC Anesthesiol"},{"key":"1701_CR65","unstructured":"Marti FS, G; Mauch J. Economic considerations for the use of Sugammadex in a Swiss Department of Anaesthesiology. An\u00e4sth Intensivmed. 2017;58:325\u201329."},{"key":"1701_CR66","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f1460","volume":"346","author":"MJ Meyer","year":"2013","unstructured":"Meyer MJ, Bateman BT, Kurth T, et al. Neostigmine reversal doesn\u2019t improve postoperative respiratory safety. BMJ. 2013;346:f1460.","journal-title":"BMJ"},{"key":"1701_CR67","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.accpm.2016.06.004","volume":"35","author":"T Fuchs-Buder","year":"2016","unstructured":"Fuchs-Buder T. Neostigmine: timing and dosing in 2016. Anaesth Crit Care Pain Med. 2016;35:245\u20137.","journal-title":"Anaesth Crit Care Pain Med"},{"key":"1701_CR68","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1001\/jamasurg.2016.4065","volume":"152","author":"A Fernandez-Bustamante","year":"2017","unstructured":"Fernandez-Bustamante A, Frendl G, Sprung J, et al. Postoperative pulmonary complications, early mortality, and hospital stay following noncardiothoracic surgery: a multicenter study by the Perioperative Research Network Investigators. JAMA Surg. 2017;152:157\u201366.","journal-title":"JAMA Surg"},{"key":"1701_CR69","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12871-020-00962-7","volume":"20","author":"TK Oh","year":"2020","unstructured":"Oh TK, Ryu JH, Nam S, et al. Association of neuromuscular reversal by sugammadex and neostigmine with 90-day mortality after non-cardiac surgery. BMC Anesthesiol. 2020;20:41.","journal-title":"BMC Anesthesiol."},{"key":"1701_CR70","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1213\/ANE.0000000000004752","volume":"132","author":"MA Burbridge","year":"2021","unstructured":"Burbridge MA. Incidence of anaphylaxis to sugammadex in a single-center cohort of 19,821 patients. Anesth Analg. 2021;132:93\u20137.","journal-title":"Anesth Analg"},{"key":"1701_CR71","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.bja.2019.10.016","volume":"124","author":"M Orihara","year":"2020","unstructured":"Orihara M, Takazawa T, Horiuchi T, et al. Comparison of incidence of anaphylaxis between sugammadex and neostigmine: a retrospective multicentre observational study. Br J Anaesth. 2020;124:154\u201363.","journal-title":"Br J Anaesth"},{"key":"1701_CR72","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1213\/ANE.0000000000002562","volume":"126","author":"Y Miyazaki","year":"2018","unstructured":"Miyazaki Y, Sunaga H, Kida K, et al. Incidence of anaphylaxis associated with sugammadex. Anesth Analg. 2018;126:1505\u20138.","journal-title":"Anesth Analg"},{"key":"1701_CR73","doi-asserted-by":"crossref","unstructured":"Batistaki C, Vagdatli K, Tsiotou A, et al. A multicenter survey on the use of neuromuscular blockade in Greece. Does the real-world clinical practice indicate the necessity of guidelines? J Anaesthesiol Clin Pharmacol. 2019;35:202\u201314.","DOI":"10.4103\/joacp.JOACP_195_18"},{"key":"1701_CR74","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1213\/ANE.0b013e3181c07428","volume":"111","author":"M Naguib","year":"2010","unstructured":"Naguib M, Kopman AF, Lien CA, et al. A survey of current management of neuromuscular block in the United States and Europe. Anesth Analg. 2010;111:110\u20139.","journal-title":"Anesth Analg"},{"key":"1701_CR75","first-page":"45","volume":"26","author":"A Pongracz","year":"2019","unstructured":"Pongracz A, Nemes R, Breazu C, et al. International survey of neuromuscular monitoring in two European countries: a questionnaire study among Hungarian and Romanian anaesthesiologists. Rom J Anaesth Intensive Care. 2019;26:45\u201351.","journal-title":"Rom J Anaesth Intensive Care"},{"key":"1701_CR76","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1213\/ANE.0000000000005080","volume":"131","author":"TZ Dubovoy","year":"2020","unstructured":"Dubovoy TZ, Saager L, Shah NJ, et al. Utilization patterns of perioperative neuromuscular blockade reversal in the united states: a retrospective observational study from the multicenter perioperative outcomes group. Anesth Analg. 2020;131:1510\u20139.","journal-title":"Anesth Analg"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01701-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01701-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01701-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T15:15:30Z","timestamp":1686323730000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01701-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,19]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1701"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01701-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,19]]},"assertion":[{"value":"10 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}